HCPCS Level II code G0103 denotes a prostate cancer screening service using the prostate specific antigen (PSA) test. Nationally, PSA screening remains a high-volume preventive service with implications for public health screening programs, primary care workflows, and laboratory billing operations. The code identifies a distinct screening encounter separate from diagnostic PSA testing and is important for tracking preventive care utilization and payer coverage policies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of payer coverage patterns, benchmark metrics, and relevant policy context for PSA screening reimbursement. The publication highlights typical sites of service, common billing modifiers, and operational considerations affecting claims adjudication. It also summarizes where practice managers and coders should look for payer-specific guidance and coding clarifications.

This summary provides clinical context for why PSA screening is coded separately, outlines expected claims workflows, and flags areas where national policy updates can affect coverage and billing. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.